Tags

Type your tag names separated by a space and hit enter

Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus.
J Formos Med Assoc. 2011 May; 110(5):316-21.JF

Abstract

BACKGROUND/PURPOSE

Serum autoantibodies, including antinuclear antibodies (ANAs), have been found in patients with oral lichen planus (OLP). This study evaluated whether Taiwanese OLP patients had significantly higher frequencies of serum ANAs than healthy control subjects, and whether levamisole treatment could modulate the antibody levels.

METHODS

This study used an indirect immunofluorescence technique to measure the baseline serum levels of ANA in a group of 583 Taiwanese OLP patients and 53 healthy control subjects. Seventy-nine ANA-positive OLP patients were treated with levamisole under a regular follow-up schedule in our dental clinic, and their serum ANA levels were measured after treatment.

RESULTS

We found that the frequencies of serum ANA in patients with OLP (23.2%), erosive OLP (EOLP, 23.8%), major EOLP (31.5%), and minor EOLP (18.1%) were all significantly higher than that (5.7%) in healthy control subjects. In addition, major EOLP patients had a significantly higher serum ANA positive rate than minor EOLP or non-erosive OLP patients. Of 135 ANA-positive OLP patients, 79 were treated with levamisole under a regular follow-up schedule. We found that treatment with levamisole for a period of 2-38 months (mean, 12 ± 9 months) effectively reduced the high mean serum ANA titer (557 ± 98) at baseline to an undetectable level (0) in all ANA-positive OLP patients, regardless of different high initial serum titers of ANA.

CONCLUSION

There was a significantly higher frequency of serum ANA (23.2%) in Taiwanese OLP patients than in healthy control subjects. Treatment with levamisole for 2-38 months reduced the high serum ANA to an undetectable level, and significantly improved the signs and symptoms in all treated OLP patients.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Lin HP
Graduate Institute of Clinical Dentistry, National Taiwan University, Taipei, Taiwan.
Wang YP
No affiliation info available
Chia JS
No affiliation info available
Sun A
No affiliation info available

MeSH

Adjuvants, ImmunologicAdultAgedAged, 80 and overAntibodies, AntinuclearFemaleFluorescent Antibody Technique, IndirectHumansLevamisoleLichen Planus, OralMaleMiddle Aged

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21621152

Citation

Lin, Hung-Pin, et al. "Modulation of Serum Antinuclear Antibody Levels By Levamisole Treatment in Patients With Oral Lichen Planus." Journal of the Formosan Medical Association = Taiwan Yi Zhi, vol. 110, no. 5, 2011, pp. 316-21.
Lin HP, Wang YP, Chia JS, et al. Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus. J Formos Med Assoc. 2011;110(5):316-21.
Lin, H. P., Wang, Y. P., Chia, J. S., & Sun, A. (2011). Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus. Journal of the Formosan Medical Association = Taiwan Yi Zhi, 110(5), 316-21. https://doi.org/10.1016/S0929-6646(11)60047-8
Lin HP, et al. Modulation of Serum Antinuclear Antibody Levels By Levamisole Treatment in Patients With Oral Lichen Planus. J Formos Med Assoc. 2011;110(5):316-21. PubMed PMID: 21621152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus. AU - Lin,Hung-Pin, AU - Wang,Yi-Ping, AU - Chia,Jean-San, AU - Sun,Andy, PY - 2010/03/25/received PY - 2010/04/14/revised PY - 2010/04/16/accepted PY - 2011/5/31/entrez PY - 2011/5/31/pubmed PY - 2011/10/14/medline SP - 316 EP - 21 JF - Journal of the Formosan Medical Association = Taiwan yi zhi JO - J Formos Med Assoc VL - 110 IS - 5 N2 - BACKGROUND/PURPOSE: Serum autoantibodies, including antinuclear antibodies (ANAs), have been found in patients with oral lichen planus (OLP). This study evaluated whether Taiwanese OLP patients had significantly higher frequencies of serum ANAs than healthy control subjects, and whether levamisole treatment could modulate the antibody levels. METHODS: This study used an indirect immunofluorescence technique to measure the baseline serum levels of ANA in a group of 583 Taiwanese OLP patients and 53 healthy control subjects. Seventy-nine ANA-positive OLP patients were treated with levamisole under a regular follow-up schedule in our dental clinic, and their serum ANA levels were measured after treatment. RESULTS: We found that the frequencies of serum ANA in patients with OLP (23.2%), erosive OLP (EOLP, 23.8%), major EOLP (31.5%), and minor EOLP (18.1%) were all significantly higher than that (5.7%) in healthy control subjects. In addition, major EOLP patients had a significantly higher serum ANA positive rate than minor EOLP or non-erosive OLP patients. Of 135 ANA-positive OLP patients, 79 were treated with levamisole under a regular follow-up schedule. We found that treatment with levamisole for a period of 2-38 months (mean, 12 ± 9 months) effectively reduced the high mean serum ANA titer (557 ± 98) at baseline to an undetectable level (0) in all ANA-positive OLP patients, regardless of different high initial serum titers of ANA. CONCLUSION: There was a significantly higher frequency of serum ANA (23.2%) in Taiwanese OLP patients than in healthy control subjects. Treatment with levamisole for 2-38 months reduced the high serum ANA to an undetectable level, and significantly improved the signs and symptoms in all treated OLP patients. SN - 0929-6646 UR - https://www.unboundmedicine.com/medline/citation/21621152/Modulation_of_serum_antinuclear_antibody_levels_by_levamisole_treatment_in_patients_with_oral_lichen_planus_ DB - PRIME DP - Unbound Medicine ER -